Search - tctmd.com

Displaying 21 - 40 of 55

Sort: Relevancy | Date

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Microvascular Disease Quadruples Risk of Leg Amputation

L.A. McKeown

July 08, 2019

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

News Daily News

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

Shelley Wood

November 23, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Yael L. Maxwell

January 09, 2018

News Daily News

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

L.A. McKeown

December 11, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Shelley Wood

September 28, 2016

News Daily News

研究显示糖尿病患者急性心梗后风险差异很大

L.A. McKeown

May 26, 2016

News Daily News

Un Estudio Revela un Sorprendente Rango de Riesgo Post-IAM entre Pacientes con Diabetes

L.A. McKeown

May 26, 2016

News Daily News

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

L.A. McKeown

May 26, 2016

Presentation

Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus

Presenter: Suzanne V. Arnold

May 25, 2016

News Daily News

尽管有指南说明，但糖尿病患者多支 CAD 患者接受 PCI 的人数仍多于 CABG

Yael L. Maxwell

May 13, 2016

News Daily News

A Pesar de las Directrices, Más Diabéticos con EAC Multivaso son sometidos a PCI que a CABG

Yael L. Maxwell

May 13, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Industry News

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

March 06, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

Advertisement

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Microvascular Disease Quadruples Risk of Leg Amputation

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

研究显示糖尿病患者急性心梗后风险差异很大

Un Estudio Revela un Sorprendente Rango de Riesgo Post-IAM entre Pacientes con Diabetes

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus

尽管有指南说明，但糖尿病患者多支 CAD 患者接受 PCI 的人数仍多于 CABG

A Pesar de las Directrices, Más Diabéticos con EAC Multivaso son sometidos a PCI que a CABG

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content